Neomorph
Neomorph, based in San Diego, California, is a venture-backed biotechnology company specializing in targeted protein degradation to develop treatments for previously 'undruggable' proteins and diseases.
Company Overview
Neomorph is a biotechnology company headquartered in San Diego, California. The company focuses on advancing the science of targeted protein degradation, aiming to develop therapies for 'undruggable' proteins that are implicated in various diseases. Neomorph is venture-backed and collaborates closely with the Center for Protein Degradation at the Dana Farber Cancer Institute.
Targeted Protein Degradation
Neomorph specializes in the discovery and development of innovative medicines using its proprietary targeted protein degradation platform. This scientific approach aims to address 'undruggable' targets, which are proteins that have historically been challenging to treat with conventional drugs. The company is dedicated to pioneering new therapeutic solutions to cure diseases by degrading these proteins.
Funding and Financial Backing
Neomorph has raised $109 million in Series A financing to advance its proprietary targeted protein degradation platform and specific programs. This significant venture capital investment underlines the confidence in Neomorph's innovative approach and potential to develop groundbreaking therapies.
Collaborations and Partnerships
Neomorph has entered into a multi-target collaboration with Novo Nordisk to discover novel molecular glue degraders. This collaboration focuses on developing treatments for cardiometabolic and rare diseases and has a potential deal value of $1.46 billion. Additionally, Neomorph collaborates closely with the Center for Protein Degradation at the Dana Farber Cancer Institute to further its research and development efforts.